Evidence map›Paper›PMID 39105914›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Generation of Directly Reprogrammed Human Endothelial Cells.

Seonggeon Cho, Iris Xia, Sangho Lee, Changwon Park, Young-Sup Yoon

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Seonggeon ChoDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Iris XiaDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Sangho LeeDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Changwon ParkLouisiana State University Health Sciences Center, Department of Molecular & Cellular Physiology, Shreveport, LA, USA.
Young-Sup YoonDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. yyoon5@emory.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Direct reprogramming provides a novel breakthrough for generating functional endothelial cells (ECs) without the need for intermediate stem or progenitor states, offering a promising resource for cardiovascular research and treatment. ETV2 is a key transcription factor that has been identified as a pioneering factor for specifying endothelial lineage. Achieving precise ETV2 induction is essential for effective endothelial reprogramming, and maintaining the reprogrammed cellular phenotype relies on a specific combination of growth factors and small molecules. Thus, we hereby provide a straightforward and comprehensive protocol for generating two distinct types of reprogrammed ECs (rECs) from human dermal fibroblasts (HDFs). Early rECs demonstrate a robust neovascularization property but lack the mature EC phenotype, while late rECs exhibit phenotypical similarity to human postnatal ECs and have a neovascularization capacity similar to early rECs. Both cell types can be derived from human somatic source cells, making them suitable for personalized disease investigations, drug discovery, and disease therapy.

Indexed as

Cell Culture TechniquesCellular ReprogrammingEndothelial CellsFibroblastsCell DifferentiationCells, CulturedCellular Reprogramming TechniquesHumansNeovascularization, PhysiologicTranscription FactorsTranscription FactorsDirect reprogrammingEndothelial cellsER71/ETV2NeovascularizationTransdifferentiation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.